Your browser doesn't support javascript.
Impact of severe acute respiratory syndrome coronavirus-2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group.
Steffanoni, Sara; Calimeri, Teresa; Laurenge, Alice; Fox, Christopher P; Soussain, Carole; Grommes, Christian; Tisi, Maria Chiara; Boot, Jesca; Crosbie, Nicola; Visco, Carlo; Arcaini, Luca; Chaganti, Sridhar; Sassone, Marianna C; Alencar, Alvaro; Armiento, Daniele; Romano, Ilaria; Dietrich, Jorg; Itchaki, Gilad; Bruna, Riccardo; Fracchiolla, Nicola S; Arletti, Laura; Venditti, Adriano; Booth, Stephen; Musto, Pellegrino; Hoang Xuan, Khê; Batchelor, Tracy T; Cwynarski, Kate; Ferreri, Andrés J M.
  • Steffanoni S; Lymphoma Unit, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Calimeri T; Lymphoma Unit, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Laurenge A; Service de Neurologie 2-Mazarin, Hôpitaux Universitaires La Pitié Salpêtrière, APHP, Sorbonne Université, Paris, France.
  • Fox CP; Hematology Department, University Hospitals NHS Trust, Nottingham, UK.
  • Soussain C; Hôpital René Huguenin-Institut Curie, Saint-Cloud, Paris, France.
  • Grommes C; Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Tisi MC; Division of Hematology, Ospedale San Bortolo, Vicenza, Italy.
  • Boot J; Barking, Havering and Redbridge University Hospitals NHS Trust, London, UK.
  • Crosbie N; Derriford Hospital, Plymouth, UK.
  • Visco C; Department of Medicine, Section of Hematology, University of Verona, Verona, Italy.
  • Arcaini L; Division of Hematology, Fondazione IRCCS Policlinico San Matteo and Department of Molecular Medicine, University of Pavia, Pavia, Italy.
  • Chaganti S; Department of Haematology, Queen Elizabeth Hospital, Birmingham, UK.
  • Sassone MC; Lymphoma Unit, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
  • Alencar A; Department of Hematology and Oncology, University of Miami/Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
  • Armiento D; Division of Hematology, Campus Bio Medico, Rome, Italy.
  • Romano I; Division of Hematology, Ospedale Careggi, Florence, Italy.
  • Dietrich J; Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, Boston, Massachusetts, USA.
  • Itchaki G; Institute of Hematology, Davidoff Cancer Center, Rabin Medical Center, Petah-Tikva, Israel.
  • Bruna R; Division of Hematology, Ospedale Maggiore, Novara, Italy.
  • Fracchiolla NS; UOC Ematologia, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy.
  • Arletti L; Division of Hematology, Azienda USL-IRCCS of Reggio Emilia, Reggio Emilia, Italy.
  • Venditti A; Department of Biomedicine and Prevention, University Tor Vergata, Rome, Italy.
  • Booth S; NIHR Oxford Biomedical Research Centre, Churchill Hospital, Oxford, UK.
  • Musto P; Department of Emergency and Organ Transplantation, 'Aldo Moro' University School of Medicine, and Unit of Hematology and Stem Cell Transplantation, AOUC Policlinico, Bari, Italy.
  • Hoang Xuan K; Service de Neurologie 2-Mazarin, Hôpitaux Universitaires La Pitié Salpêtrière, APHP, Sorbonne Université, Paris, France.
  • Batchelor TT; Department of Neurology, Brigham and Women's Hospital, Boston, Massachusetts, USA.
  • Cwynarski K; Department of Haematology, University College London Hospital, London, UK.
  • Ferreri AJM; Lymphoma Unit, Department of Onco-Hematology, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Br J Haematol ; 199(4): 507-519, 2022 11.
Article in English | MEDLINE | ID: covidwho-1978426
ABSTRACT
To optimise management of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection identifying high-risk patients and maintaining treatment dose intensity is an important issue in patients with aggressive lymphomas. In the present study, we report on the presentation, management, and outcome of an international series of 91 patients with primary central nervous system lymphoma and SARS-CoV-2 infection. SARS-CoV-2 was diagnosed before/during first-line treatment in 64 patients, during follow-up in 21, and during salvage therapy in six. Among the 64 patients infected before/during first-line chemotherapy, 38 (59%) developed pneumonia and 26 (41%) did not clear the virus. Prolonged exposure to steroids before viral infection and/or treatment with high-dose cytarabine favoured pneumonia development and virus persistence and were associated with poorer survival; 81% of patients who did not clear virus died early from coronavirus disease 2019 (COVID-19). Vaccination was associated with lower pneumonia incidence and in-hospital mortality. Chemotherapy was initiated/resumed in 43 (67%) patients, more commonly among patients who did not develop pneumonia, cleared the virus, or did not receive steroids during infection. Chemotherapy resumption in patients with viral persistence should be indicated cautiously as it was associated with a poorer survival (6-month, 70% and 87%, p = 0.07). None of the 21 patients infected during follow-up died from COVID-19, requiring similar measures as infected subjects in the general population.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Lymphoma Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Br J Haematol Year: 2022 Document Type: Article Affiliation country: Bjh.18396

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / Lymphoma Type of study: Cohort study / Experimental Studies / Observational study / Prognostic study Topics: Vaccines Limits: Humans Language: English Journal: Br J Haematol Year: 2022 Document Type: Article Affiliation country: Bjh.18396